Depression, Inflammation and Tryptophan Metabolism

The Wiley-Blackwell Handbook of Psychoneuroimmunology

Volumn , Issue , 2013, Pages 448-468

  McCusker, Robert H ^a   Kavelaars, Annemieke ^a,b,c   Heijnen, Cobi J ^b,c   Dantzer, Robert ^a,c   Kelley, Keith W ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brain; Depression; Dioxygenase expression; Inflammation; Kynurenine pathway; Tryptophan metabolism

Indexed keywords

EID: 84912122551     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118314814.ch23     Document Type: Chapter

References (64)

1. Anderson, G. (2011). Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Medical Hypotheses, 76(1), 54-60.
2. Anderson, G., and Rodriguez, M. (2011). Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin. European Journal of Neurology, 18(5), 680-685.
3. Baran, H., Jellinger, K., and Deecke, L. (1999). Kynurenine metabolism in Alzheimer’s disease. Journal of Neural Transmission, 106(2), 165-181.
4. Beagles, K. E., Morrison, P. F., and Heyes, M. P. (1998). Quinolinic acid in vivo synthesis rates, extracellular concentrations, and intercompartmental distributions in normal and immune-activated brain as determined by multiple-isotope microdialysis. Journal of Neurochemistry, 70(1), 281-291.
5. Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., and Bird, E. D. (1990). Kynurenine pathway measurements in Huntington’s disease striatum: evidence for reduced formation of kynurenic acid. Journal of Neurochemistry, 55(4), 1327-1339.
6. Blalock, J. E. (1984). The immune system as a sensory organ. Journal of Immunology, 132(3), 1067-1070.
7. Braidy, N., Grant, R., Adams, S., Brew, B. J., and Guillemin, G. J. (2009). Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotoxicity Research, 16(1), 77-86.
8. Capuron, L., and Dantzer, R. (2003). Cytokines and depression: the need for a new paradigm. Brain, Behavior, and Immunity, 17 Suppl 1, S119-124.
9. Capuron, L., Gumnick, J. F., Musselman, D. L., Lawson, D. H., Reemsnyder, A., Nemeroff, C. B., and Miller, A. H. (2002). Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology, 26(5), 643-652.
10. Coppen, A. (1967). The biochemistry of affective disorders. British Journal of Psychiatry, 113(504), 1237-1264.
11. Corona, A. W., Huang, Y., O’Connor, J. C., Dantzer, R., Kelley, K. W., Popovich, P. G., and Godbout, J. P. (2010). Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. Journal of Neuroinflammation, 7, 93.
12. Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W., and Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46-56.
13. Evans, D. L., Charney, D. S., Lewis, L., Golden, R. N., Gorman, J. M., Krishnan, K. R., …Valvo, W. J. (2005). Mood disorders in the medically ill: scientific review and recommendations. Biological Psychiatry, 58(3), 175-189.
14. Felger, J. C., Alagbe, O., Hu, F., Mook, D., Freeman, A. A., Sanchez, M. M., … Miller, A. H. (2007). Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biological Psychiatry, 62(11), 1324-1333.
15. Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., and Smith, Q. R. (1991). Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. Journal of Neurochemistry, 56(6), 2007-2017.
16. Guidetti, P., Luthi-Carter, R. E., Augood, S. J., and Schwarcz, R. (2004). Neostriatal and cortical quinolinate levels are increased in early grade Huntington’s disease. Neurobiology of Disease, 17(3), 455-461.
17. Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., and Cullen, K. M. (2005a). Indoleamine 2, 3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus. Neuropathology and Applied Neurobiology, 31(4), 395-404.
18. Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., … Brew, B. J. (2007). Characterization of the kynurenine pathway in human neurons. Journal of Neuroscience, 27(47), 12884-12892.
19. Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., … Brew, B. J. (2001). Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. Journal of Neurochemistry, 78(4), 842-853.
20. Guillemin, G. J., Smith, D. G., Kerr, S. J., Smythe, G. A., Kapoor, V., Armati, P. J., and Brew, B. J. (2000). Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Report, 5(2-3), 108-111.
21. Guillemin, G. J., Smythe, G., Takikawa, O., and Brew, B. J. (2005b). Expression of indoleamine 2, 3- dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia, 49(1), 15-23.
22. Hansen, A. M., Driussi, C., Turner, V., Takikawa, O., and Hunt, N. H. (2000). Tissue distribution of indoleamine 2, 3-dioxygenase in normal and malaria-infected tissue. Redox Report, 5(2-3), 112-115.
23. Henry, C. J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M. T., … Godbout, J. P. (2008). Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. Journal of Neuroinflammation, 5, 15.
24. Henry, C. J., Huang, Y., Wynne, A. M., and Godbout, J. P. (2009). Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain, Behavior, and Immunity, 23(3), 309-317.
25. Heyes, M. P., Saito, K., Crowley, J. S., Davis, L. E., Demitrack, M. A., Der, M., … et al. (1992). Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain, 115 (Pt 5), 1249-1273.
26. Hilmas, C., Pereira, E. F., Alkondon, M., Rassoulpour, A., Schwarcz, R., and Albuquerque, E. X. (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. Journal of Neuroscience, 21(19), 7463-7473.
27. Hochstrasser, T., Ullrich, C., Sperner-Unterweger, B., and Humpel, C. (2011). Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2, 3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience, 184, 128-138.
28. Jauch, D., Urbanska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J. P., Whetsell, W. O., Jr., and Schwarcz, R. (1995). Dysfunction of brain kynurenic acid metabolism in Huntington’s disease: focus on kynurenine aminotransferases. Journal of Neurological Science, 130(1), 39-47.
29. Jhamandas, K. H., Boegman, R. J., Beninger, R. J., Miranda, A. F., and Lipic, K. A. (2000). Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotoxicity Research, 2(2-3), 139-155.
30. Kalisch, B. E., Jhamandas, K., Boegman, R. J., and Beninger, R. J. (1994). Picolinic acid protects against quinolinic acid-induced depletion of NADPH diaphorase containing neurons in the rat striatum. Brain Research, 668(1-2), 1-8.
31. Kocki, T., Wnuk, S., Kloc, R., Kocki, J., Owe-Larsson, B., and Urbanska, E. M. (2011). New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. Journal of Neural Transmission, 119(2), 235-243.
32. Kwidzinski, E., Bunse, J., Aktas, O., Richter, D., Mutlu, L., Zipp, F., … Bechmann, I. (2005). Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB Journal, 19(10), 1347-1349.
33. Kwidzinski, E., Bunse, J., Kovac, A. D., Ullrich, O., Zipp, F., Nitsch, R., and Bechmann, I. (2003). IDO (indolamine 2, 3-dioxygenase) expression and function in the CNS. Adv Exp Med Biol, 527, 113-118.
34. Lepine, J. P., and Briley, M. (2011). The increasing burden of depression. Neuropsychiatric Disease and Treatment, 7(Suppl 1), 3-7.
35. Liimatainen, S., Lehtimaki, K., Raitala, A., Peltola, M., Oja, S. S., Peltola, J., and Hurme, M. A. (2011). Increased indoleamine 2, 3-dioxygenase (IDO) activity in idiopathic generalized epilepsy. Epilepsy Research, 94, 206-212
36. Lim, C. K., Smythe, G. A., Stocker, R., Brew, B. J., and Guillemin, G. J. (2007). Characterization of the kynurenine pathway in human oligodendrocytes. International Congress Series, 1304, 213-217.
37. Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., and Verkerk, R. (2011). The new '5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Progress in Neuropsychopharmacology and Biological Psychiatry, 35(3), 702-721.
38. Metz, R., Duhadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., and Prendergast, G. C. (2007). Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Research, 67(15), 7082-7087.
39. Miller, C. L., Llenos, I. C., Dulay, J. R., Barillo, M. M., Yolken, R. H., and Weis, S. (2004). Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiology of Disease, 15(3), 618-629.
40. Miller, C. L., Llenos, I. C., Dulay, J. R., and Weis, S. (2006). Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Research, 1073-1074, 25-37.
41. Moreau, M., Lestage, J., Verrier, D., Mormede, C., Kelley, K. W., Dantzer, R., and Castanon, N. (2005). Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2, 3-dioxygenase in mice. Journal of Infectious Diseases, 192(3), 537-544.
42. Myint, A. M., Kim, Y. K., Verkerk, R., Scharpe, S., Steinbusch, H., and Leonard, B. (2007). Kynurenine pathway in major depression: evidence of impaired neuroprotection. Journal of Affective Disorders, 98(1-2), 143-151.
43. Nemeth, H., Toldi, J., and Vecsei, L. (2005). Role of kynurenines in the central and peripheral nervous systems. Current Neurovascular Research, 2(3), 249-260.
44. O’Connor, J. C., Andre, C., Wang, Y., Lawson, M. A., Szegedi, S. S., Lestage, J., … Dantzer, R. (2009). Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3- dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. Journal of Neuroscience, 29(13), 4200-4209.
45. O’Connor, J. C., Lawson, M. A., Andre, C., Briley, E. M., Szegedi, S. S., Lestage, J., … Kelley, K. W. (2009). Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. Journal of Immunology, 182(5), 3202-3212.
46. O’Connor, J. C., Lawson, M. A., Andre, C., Moreau, M., Lestage, J., Castanon, N., … Dantzer, R. (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3- dioxygenase activation in mice. Molecular Psychiatry, 14(5), 511-522.
47. Ogawa, T., Matson, W. R., Beal, M. F., Myers, R. H., Bird, E. D., Milbury, P., and Saso, S. (1992). Kynurenine pathway abnormalities in Parkinson’s disease. Neurology, 42(9), 1702-1706.
48. Ohira, K., Hagihara, H., Toyama, K., Takao, K., Kanai, M., Funakoshi, H., … Miyakawa, T. (2010). Expression of tryptophan 2, 3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Molecular Brain, 3(1), 26.
49. Owe-Young, R., Webster, N. L., Mukhtar, M., Pomerantz, R. J., Smythe, G., Walker, D., … Brew, B. J. (2008). Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. Journal of Neurochemistry, 105(4), 1346-1357.
50. Park, S. E., Dantzer, R., Kelley, K. W., and McCusker, R. H. (2011). Central administration of insulinlike growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. Journal of Neuroinflammation, 8, 12.
51. Park, S. E., Lawson, M. A., Dantzer, R., Kelley, K. W., and McCusker, R.H. (2011). Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. Journal of Neuroinflammation, 8 179.
52. Perkins, M. N., and Stone, T. W. (1982). An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Research, 247(1), 184-187.
53. Pocivavsek, A., Wu, H. Q., Potter, M. C., Elmer, G. I., Pellicciari, R., and Schwarcz, R. (2011). Fluctuations in endogenous kynurenic Acid control hippocampal glutamate and memory. Neuropsychopharmacology, 36(11), 2357-2367.
54. Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., … Miller, A. H. (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Molecular Psychiatry, 15(4), 393-403.
55. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., and Pollmacher, T. (2001). Cytokine-associated emotional and cognitive disturbances in humans. Archives of General Psychiatry, 58(5), 445-452.
56. Roy, E. J., Takikawa, O., Kranz, D. M., Brown, A. R., and Thomas, D. L. (2005). Neuronal localization of indoleamine 2, 3-dioxygenase in mice. Neuroscience Letters, 387(2), 95-99.
57. Schwarcz, R., Speciale, C., and French, E. D. (1987). Hippocampal kynurenines as etiological factors in seizure disorders. Polish Journal of Pharmacology and Pharmacy, 39(5), 485-494.
58. Schwarcz, R., Speciale, C., Okuno, E., French, E. D., and Kohler, C. (1986). Quinolinic acid: a pathogen in seizure disorders? Advances in Experimental Medicine and Biology, 203, 697-707.
59. Simones, T., and Shepherd, D. M. (2011). Consequences of AhR activation in steady-state dendritic cells. Toxicological Sciences, 119(2), 293-307.
60. Smith, R. S. (1991). The macrophage theory of depression. Medical Hypotheses, 35(4), 298-306.
61. Stone, T. W., and Perkins, M. N. (1981). Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. European Journal of Pharmacology, 72(4), 411-412.
62. Wang, Y., Lawson, M. A., Kelley, K. W., and Dantzer, R. (2010). Primary murine microglia are resistant to nitric oxide inhibition of indoleamine 2, 3-dioxygenase. Brain, Behavior, and Immunity, 24(8), 1249-1253.
63. Wonodi, I., and Schwarcz, R. (2010). Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophrenia Bulletin, 36(2), 211-218.
64. Wu, H. Q., Rassoulpour, A., and Schwarcz, R. (2007). Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? Journal of Neural Transmission, 114(1), 33-41.